EI
OVID icon

EAM Investors’s Ovid Therapeutics OVID Stock Holding History

EAM Investors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$698K Sell
259,631
-10,667
-4% -$27.5K 0.06% 257
2026
Q1 		$600K Buy
+270,298
New +$483K 0.07% 253
2020
Q4 		– Sell
-121,116
Closed -$695K – 364
2020
Q3 		$695K Sell
121,116
-63,612
-34% -$426K 0.16% 248
2020
Q2 		$1.36M Hold
184,728
– – 0.3% 162
2020
Q1 		$550K Sell
184,728
-100,337
-35% -$338K 0.17% 193
2019
Q4 		$1.18M Buy
285,065
+78,947
+38% +$249K 0.26% 179
2019
Q3 		$668K Buy
+206,118
New +$468K 0.18% 211

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

EAM Investors's OVID Position: Q2 2026 in Review

EAM Investors reduced its Ovid Therapeutics (OVID) stake by 3.9% in Q2 2026, selling an estimated $27.5K and leaving 259,631 shares worth $698K. The position accounts for 0.06% of the portfolio, ranked #257.

EAM Investors first reported a position in OVID in Q3 2019 and has held it in 7 quarters since. The position peaked at $1.36M in Q2 2020. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • EAM Investors held 259,631 shares of Ovid Therapeutics worth $698K as of Q2 2026.
  • EAM Investors sold 10,667 Ovid Therapeutics shares in Q2 2026, an estimated $27.5K.
  • Ovid Therapeutics made up 0.06% of EAM Investors's portfolio in Q2 2026, its #257 holding.
  • EAM Investors first reported a position in Ovid Therapeutics in Q3 2019 and has held it in 7 quarters since.
  • EAM Investors's Ovid Therapeutics position peaked at $1.36M in Q2 2020.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.